AIFF (Firefly Neuro) Market Value to Book Value Ratio

Official company branding of Firefly Neuroscience, Inc. (AIFF)

The price action of Firefly Neuroscience, Inc (AIFF) securities on the GURU.Markets platform reflects the dynamics of an asset currently valued at 1.09. Firefly Neuroscience, Inc is developing a cutting-edge Brain Network Analytics system for high-precision brain function studies. The business is developing AI-based software for objective EEG analysis in psychiatry. Top management's strategy focuses on launching digital diagnostic services to the market to support medical professionals.

AIFF - fireflyneuro.com Market-to-Book Ratio over the range 07/04/2022 - 10/28/2026
Original product of Firefly Neuroscience Inc

For the Firefly Neuroscience, Inc (AIFF) investor, this indicator serves as a tool for assessing market optimism regarding tangible assets. The market cap-to-book value ratio is calculated as the ratio of the company's market capitalization to its net equity. An increase in this coefficient signals inflated market expectations. For Firefly Neuroscience, Inc (AIFF), such a premium is justified by the implementation of AI-driven EEG diagnostics in psychiatry. The synergy of cloud technologies and clinical data creates intangible value that exceeds balance sheet figures.

Competitor analysis

Market Capitalization to Book Value Ratio Biogen Inc. (BIIB)|NBIX (neurocrine.com) - Market Capitalization to Net Assets|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Amylyx Pharmaceuticals AMLX|Market Capitalization to Net Assets trevitherapeutics.com|PRAX (Praxis Precision Medicines, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value AVXL (Anavex)|Market Value to Book Value Ratio CeriBell Corp|Market Value to Book Value Prothena PRTA|ALEC (Alector Therapeutics) - Market Capitalization to Book Value Ratio|ANNX - Market-to-Book Ratio|Market Capitalization to Book Value Ratio omeros.com (OMER)|NGNE (Neurogene Inc) - Market Capitalization to Net Assets|Market Value to Book Value Ratio AC Immune Corp|Market Value to Book Value Ratio Voyager Corp (VYGR)|Neumora Therapeutics - Market Cap to Net Assets Ratio|Market-to-Book Ratio scilexholding.com SCLX|Market Cap to Net Assets Ratio Tevogen Bio|Alpha Cognition Inc - Market Value to Book Value|Cognition Therapeutics, Inc. (CGTX) - Market Value to Book Value Ratio|IKT - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SAVA|Market-to-Book Ratio Assertio|COYA (Coya Therapeutics Inc) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio VTGN|Ovid Therapeutics Inc. (OVID) - Market Value to Book Value Ratio|Market Value to Book Value ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Market Value to Book Value Ratio|Alterity Therapeutics Ltd. - Market-to-Book Ratio|Market Value to Book Value Ratio CLNN (Clene Nanomedicine)|PEPG - Market Capitalization to Book Value|JUNS (Jupiter Neurosciences) - Market Capitalization to Book Value Ratio|Relmada Corp (RLMD) - Market Cap to Net Assets Ratio|ANVS: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Grace Tx|Klotho Neurosciences Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio NRSN (neurosense-tx.com)|RVPH - Market Value to Book Value Ratio|Capitalization to Book Value Ratio MetaVia Inc. MTVA|NRXS: Market Capitalization to Book Value Ratio|HSDT - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio PASG|Market-to-Book Ratio Neuphoria Therapeutics|NERV - Market Cap to Net Assets Ratio|Market Value to Book Value Athira Pharma Corp|ADXN (Addex Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value ALZN (alzamend.com)|CYCN - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Protagenic Therapeutics Inc. PTIX|KTTA: Market Capitalization to Book Value Ratio|CRGT - Market Cap to Net Assets Ratio|ATXI: Market Capitalization to Book Value Ratio|brainstorm-cell.com (BCLI) - Market Capitalization to Book Value Ratio|CARA: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Chromocell Therapeutics Corp|ELYM - Market Capitalization to Book Value Ratio|Market Capitalization to Net Assets intracellulartherapies.com (ITCI)|Longboard Pharmaceuticals (LBPH) - Market Capitalization to Book Value Ratio|marinuspharma.com - Market Capitalization to Net Assets|NKGen Biotech (NKGN) - Market Value to Book Value Ratio|NRBO - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SAGE|Market-to-Book Ratio Synaptogenix, Inc|TRVN (Trevena, Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio VIGL|Anew Medical, Inc. (WENA) - Market Value to Book Value Ratio|Market Value to Book Value CERE (Cerevel Therapeutics Inc)